Amanda Corder

TL;DR: This first evaluation of the safety and efficacy of HER2-CAR T cells in patients with cancer shows the cells can persist for 6 weeks without evident toxicities, setting the stage for studies that combine Her2- CAR T cells with other immunomodulatory approaches to enhance their expansion and persistence.

TL;DR: TanCAR as mentioned in this paper is a bispecific activation and targeting of T cells that can be used to increase the specificity of effector cells for malignant versus normal target cells, to offset antigen escape or to allow for targeting the tumor and its microenvironment.

TL;DR: Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays and in an orthotopic xenogeneic murine model.

TL;DR: This work created a functional chimeric antigen receptor—the TanCAR, a novel artificial molecule that mediates bispecific activation and targeting of T cells and demonstrates the feasibility of cumulative integration of structure and docking simulation data using computational tools to interrogate the design and predict the functionality of such a complex bispecial molecule.

TL;DR: It is found that miR-223 can suppress glial precursor proliferation via repression of NFIA during chick spinal cord development and demonstrates that it is a conserved proliferative mechanism across CNS development and tumorigenesis.